Citations

Clear

273 citation(s) found for "Simone, N De".

Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage
Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari, Stark, Benjamin, Johnson, Catherine O., Kaprio, Jaakko , Korja, Miikka, Krishnamurthi, Rita , Nair, Balakrishnan , Vergouwen, Mervyn D. I. , Abdelkader, Atef , Abdullahi, Auwal , Abualruz, Hasan , Abukhadijah, Hana J , Adamu, Lawan Hassan, Adegboye, Oyelola A. , Adzigbli, Leticia Akua, Agyemang‐Duah, Williams , Ahinkorah, Bright Opoku, Ahmad, Aqeel , Ahmad, Danish , Ahmadzade, Amir Mahmoud , Akkaif, Mohammed Ahmed , Ali, Mohammed Usman, Alif, Sheikh Mohammad , Alimohamadi, Yousef, Alsabri, Mohammed , Altaf, Awais , Alvis‐Guzmán, Nelson , Alwafi, Hassan , Al‐Wardat, Mohammad , Alyahya, Mohammad S. , Amin, Tarek Tawfik , Amindarolzarbi, Alireza , Amusa, Ganiyu , Angappan, Dhanalakshmi , Anuoluwa, Boluwatife Stephen, Anwar, Saleha, Anyasodor, Anayochukwu Edward , Apostol, Geminn Louis Carace, Areda, Demelash, Artamonov, Anton A, Artanti, Kurnia Dwi , Ashemo, Mubarek Yesse , Athar, Mohammad , Aujayeb, Avinash , Awotidebe, Adedapo Wasiu , Azadnajafabad, Sina , Aziz, Shahkaar , Bagheri, Nasser , Taqanaki, Pegah Bahrami , Bahramian, Saeed , Bai, Ruhai , Baig, Atif Amin , Baltatu, Ovidiu Constantin , Bam, Kiran, Barker‐Collo, Suzanne , Bärnighausen, Till , Bastan, Mohammad‐Mahdi , Basu, Sanjay , Bell, Shelly L, Benseñor, Isabela M , Berhie, Alemshet Yirga , Bhagavathula, Akshaya Srikanth , Bhaskar, Sonu , Bhat, Ajay Nagesh, Bhat, Vivek , Birhan, Mekuriaw Mesfin , Borhany, Hamed, Breitner, Susanne , Bulamu, Norma B. , Butt, Zahid A , Cabral, Lucas Scotta , Santos, Florentino Luciano Caetano dos , Cámera, Luis Alberto , Capodici, Angelo , Chadwick, Joshua , Chakraborty, Promit Ananyo , Chanie, Gashaw Sisay , Chattu, Vijay Kumar , Chi, Gerald, Chichagi, Fatemeh , Columbus, Alyssa , Criqui, Michael H, Ohadi, Mohammad Amin Dabbagh , Dadras, Omid , Dalli, Lachlan L. , Debopadhaya, Shayom , Dervišević, Emina , Devanbu, Vinoth Gnana Chellaiyan, Dewan, Syed Masudur Rahman , Dhane, Amol S. , Chi, Thanh, Phuong, Thao Huynh, Dohare, Sushil , Докова, Клара , Dowou, Robert Kokou , Dsouza, Haneil Larson , Dutta, Siddhartha , Dziedzic, Arkadiusz , E’mar, Abdel Rahman, Edvardsson, David , Efendi, Ferry, Nahas, Nevine El , Elgendy, Islam Y. , Eltaha, Chadi, Emeto, Theophilus I. , Fakhradiyev, Ildar , Faris, Pawan , Fauk, Nelsensius Klau , Fazylov, Timur, Fekadu, Ginenus , Fetensa, Getahun, Fischer, Florian, Foschi, Matteo , Fridayani, Ni Kadek Yuni, Gaipov, Abduzhappar , Gajjar, Avi A. , Ganesan, Balasankar , Gebregergis, Miglas Welay, Gebremeskel, Teferi Gebru , Getie, Molla , Ghadirian, Fataneh , Ghasemzadeh, Afsaneh , Gholamalizadeh, Maryam , Gil, Artyom , Goleij, Pouya , Goulart, Alessandra C. , Goulart, Bárbara Niegia Garcia de , Guan, Shi‐Yang , Gupta, Sapna , Habibzadeh, Farrokh , Hadi, Najah R, Hankey, Graeme J. , Harlianto, Netanja I. , Hasani, Hamidreza, Hasnain, Md Saquib , Haubold, Johannes , Havmoeller, Rasmus, Hay, Simon I , Hbid, Youssef , Heidari, Golnaz , Hiraike, Yuta, Hoan, Nguyen Quoc , Hosseinzadeh, Mehdi , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ikiroma, Adalia , Isola, Gaetano , Iwagami, Masao , Jacob, Louis, Jain, Akhil, Jakovljević, Mihajlo , Jatau, Abubakar Ibrahim , Jawaid, Talha, Jayapal, Sathish Kumar , Jonas, Jost B, Joseph, Nitin , Jürisson, Mikk , Kadashetti, Vidya, Kalani, Rizwan, Kamireddy, Arun , Kandel, Himal , Behnagh, Arman Karimi , Kashoo, Faizan , Kayode, Gbenga A , Kazemi, Foad , Khader, Yousef , Khaing, Inn Kynn , Khan, Fayaz Ahmad , Khan, Mohammad Jobair , Kashani, Hamid Reza Khayat , Khosla, Atulya Aman , Kim, Kwanghyun , Kim, Yun Jin , Korzh, Oleksii , Krishan, Kewal , Krishna, Varun, Krishnamoorthy, Vijay , Kuddus, Mohammed , Kulimbet, Mukhtar , Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Laksono, Tri, Lallukka, Tea , Latifinaibin, Kaveh, Le, Nhi Huu Hanh, Le, Thao T. , Lee, Munjae , Lee, Yo Han , Lenzi, Jacopo , Leonardi, Matilde, Li, Ming‐Chieh , Li, Xiaopan , Lim, Stephen S , Lin, Jialing , Saute, Ricardo Lutzky , Malik, Ahmad Azam , Marateb, Hamid Reza , Maroufi, Seyed Farzad , Maugeri, Andrea , McPhail, Steven , Mehndiratta, Man Mohan, Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege , Miazgowski, Tomasz , Minervini, Giuseppe , Mithra, Prasanna , Mohamed, Abdalla Z. , Mohammad, Ameen Mosa , Mohammed, Shafiu , Moni, Mohammad Ali , Moradi, Yousef, Moraga, Paula , Morawska, Lídia , Munjal, Kavita , Murray, Christopher J L , Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R. , Najdaghi, Soroush , Davani, Delaram Narimani , DELETE-ME, Nawsherwan, Nazri-Panjaki, Athare , Negoi, Ruxandra Irina , Nematollahi, Soroush , Nguyen, Hau Thi Hien, Nguyen, Hau Thi Hien, Nguyen, Phat Tuan , Nguyễn, Văn Thành , Niazi, Robina Khan, Nikoobar, Ali , Sá, Antonio Tolentino Nogueira de , Nomura, Shuhei , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ojo-Akosile, Tolulope R, Oliveira, Gláucia Maria Moraes de , Olorukooba, Abdulhakeem Abayomi , Osuagwu, Uchechukwu Levi , Ouyahia, Amel, A, Mahesh Padukudru P, Panagiotakos, Demosthenes B. , Parikh, Romil R., Park, Seoyeon , Pedersini, Paolo , Peprah, Emmanuel , Perico, Norberto, Petermann-Rocha, Fanny Emily, Plotnikov, Evgenii , Полибин, Р. В. , Postma, Maarten J. , Prasad, Manya , Qian, Gangzhen , Rahmanian, Mohammad , Rajaa, Sathish , Rajput, Prashant , Ramadan, Mahmoud M. , Rane, Amey, Rashidi, Mohammad‐Mahdi , Razo, Christian , Reddy, Murali Mohan Rama Krishna, Remuzzi, Giuseppe, Rezaei, Negar , Rezaeian, Mohsen , Rocha, Hermano Alexandre Lima , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo , Romoli, Michele, Romozzi, Marina, Roy, Nitai , Saddik, Basema Ahmad, Sahoo, Pragyan Monalisa , Salaroli, Luciane Bresciani , Samuel, Vijaya Paul, Samy, Abdallah M , Santric-Milicevic, Milena M., Saravanan, Aswini, Schlaich, Markus P. , Sethi, Yashendra , Seylani, Allen, Shaaban, Ahmed Nabil , Shafie, Mahan , Shaikh, Summaiya Zareen , Shamsutdinova, Alfiya, Sharifan, Amin , Rad, Javad Sharifi, Sharma, Vishal, Shashamo, Bereket Beyene , Shetty, Premalatha K, Shigematsu, Mika, Shorofi, Seyed Afshin, Singh, Paramdeep , Singh, Puneetpal , Singh, Surjit , Sobia, Farrukh , Solanki, Shipra, Soraneh, Soroush , Spartalis, Michael, Srinivasamurthy, Suresh Kumar , Stanikzai, Muhammad Haroon , Sun, Zhong , Swain, Chandan Kumar , Damavandi, Payam Tabaee , Tabatabaeizadeh, Seyed-Amir, Tabche, Celine , Taiba, Jabeen , Tamuzi, Jacques Lukenze , Tan, Ker‐Kan , Teramoto, Masayuki , Thakur, Ramna, Thankappan, Kavumpurathu Raman , Thayakaran, Rasiah , Thirunavukkarasu, Sathish, Ticoalu, Jansje Henny Vera, Tiwari, Krishna Raj , Tonelli, Marcello , Topór-Mądry, Roman , Tovani-Palone, Marcos Roberto Roberto, Tran, Jasmine, Tran, Thang Huu , Duc, Nguyen Tran Minh , Truelsen, Thomas Clement, Unim, Brigid, Vahdati, Sanaz, Vaithinathan, Asokan Govindaraj , Eynde, Jef Van den , Vladimirov, Sergey Konstantinovitch , Waheed, Yasir, Wahood, Waseem , Walde, Mandaras Tariku, Wang, Yanzhong , Wickramasinghe, Nuwan Darshana , Wolfe, Charles D. A., Wubie, Yihun Miskir, Xiao, Hong , Xu, Xiaoyue , Yano, Yuichiro , Yarahmadi, Amir , Ye, Pengpeng, Yon, Dong Keon , Zanghì, Aurora , Zare, Iman, Zastrozhin, Michael, Zhang, Zhi-Jiang , Zhang, Zhiqiang , Zhang, Zhiqiang, Zhao, Hanqing , Zhou, Shang Cheng, Zhumagaliuly, Abzal , Zia, Hafsa, Roth, Gregory A., Topór‐Mądry, Roman , Oliveira, Arão Belitardo , Rahim, Fakher , Saddik, Basema , Waheed, Yasir , Liu, Xuefeng , Zhang, Yunquan , Ozair, Ahmad , Buendía, Jefferson Antonio , Korja, Miikka , Baig, Atif Amin , Shanawaz, Mohd , Elgendy, Islam Y , Hankey, Graeme J , Alif, Sheikh M , Rezaei, Negar , Bhagavathula, Akshaya Srikanth , Van den Eynde, Jef , Ozair, Ahmad , Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari Matias , Volovici, Victor , Ranta, Annemarei , Rinkel, Gabriël J.E. , Abate, Yohannes Habtegiorgis, Abbastabar, Hedayat , Abd-Allah, Foad , Abdi, Parsa , Abdollahi, Arash , Abiodun, Olugbenga Olusola , Aboagye, Richard Gyan , Abouzid, Mohamed , Abtahi, Dariush , Abu‐Rumeileh, Samir , Abualhasan, Ahmed , Abu‐Zaid, Ahmed , Addo, Isaac Yeboah , Adedoyin, Rufus Adesoji , Adra, Saryia , Ahinkorah, Bright Opoku , Ahmed, Ali , Ahmed, Haroon , Ahmed, Syed Anees , Aji, Budi , Al‐Ajlouni, Yazan A. , Al‐Aly, Ziyad , ALBashtawy, Mohammed , Aljunid, Syed Mohamed , Alomari, Mahmoud A. , Alrawashdeh, Ahmad , Alsabri, Mohammed A., Salman, Rustam Al‐Shahi , Al‐Tammemi, Ala’a B. , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Alzoubi, Karem Hasan , Amani, Reza, Anderlini, Deanna , Anil, Abhishek , Arabloo, Jalal , Ärnlöv, Johan , Arumugam, Ashokan , Aryan, Zahra , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Athari, Seyyed Shamsadin , Azzam, Ahmed Y , Babu, Giridhara R. , Bako, Abdulaziz Tijjani , Banach, Maciej , Bandyopadhyay, Soham , Banik, Biswajit , Bardhan, Mainak , Barqawi, Hiba Jawdat , Barua, Lingkan , Beyene, Kebede Abera , Bhat, Vivek, Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Bijani, Ali , Bikbov, Boris , Birhanu, Mulugeta Molla , Bitra, Veera Raghavulu , Boloor, Archith , Brenner, Hermann , Bugiardini, Raffaele , Călina, Daniela Cornelia , Campos, Luciana Aparecida , Campos‐Nonato, Ismael , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catapano, Alberico Luigi , Cegolon, Luca , Chakraborty, Chiranjib , Chakraborty, Sandip , Chandika, Rama Mohan , Chaudhary, Anis Ahmad , Chi, Gerald , Ching, Patrick R , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chowdhury, E. , Chu, Dinh‐Toi , Chung, Sheng‐Chia , Silva, Alanna Gomes da , Dai, Xiaochen , Dalal, Koustuv , D’Amico, Emanuele , Dashti, Mohsen , Davletov, Kairat , Cruz-Góngora, Vanessa Vianey De la , Delgado‐Enciso, Iván , Devanbu, Vinoth Gnana Chellaiyan, Dibas, Mahmoud , Doheim, Mohamed Fahmy , Dongarwar, Deepa , D’Oria, Mario , Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Efendi, Defi , Efendi, Ferry , Elhadi, Muhammed , Eltahir, Mohd. Elmagzoub , Fabin, Natalia , Fagbamigbe, Adeniyi Francis , Fahim, Ayesha , Fares, Jawad , Ferreira, Nuno Bravo , Gandhi, Aravind P. , Garg, Ravindra Kumar , Gebrehiwot, Mesfin , Ghadimi, Delaram J. , Ghahramani, Sulmaz , Ghazy, Ramy Mohamed , Ghozy, Sherief , Gilani, Jaleed Ahmed , Gnedovskaya, Elena V. , Hadei, Mostafa , Hamidi, Samer , Hanifi, Nasrin , Haro, Josep María , Hasan, Faizul , Tabatabaei, Mahgol Sadat Hassan Zadeh , Heidari, Mohammad , Hemmati, Mehdi , Holla, Ramesh , Hostiuc, Sorin , Huang, Junjie , Huynh, Hong-Han , Ikeda, Nayu , Ilaghi, Mehran , Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Islam, Md. Rabiul , Ismail, Nahlah Elkudssiah , Iso, Hiroyasu , Jafarzadeh, Abdollah , Jairoun, Ammar Abdulrahman , Kalani, Rizwan, Kamal, Vineet Kumar , Kanchan, Tanuj , Karami, Jafar , Karaye, Ibraheem M. , Karimi, Yeganeh , Kesse‐Guyot, Emmanuelle , Khan, Fayaz, Khatatbeh, Haitham , Khatatbeh, Moawiah Mohammad , Kheirallah, Khalid Ahmed , Khidri, Feriha Fatima , Khormali, Moein , Kısa, Adnan , Kısa, Sezer , Kivimäki, Mika , Kolahi, Ali‐Asghar , Kompani, Farzad , Kostev, Karel , Kothari, Nikhil , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kusuma, Dian Palupi , Kytö, Ville , Vecchia, Carlo La , Lahariya, Chandrakant , Latief, Kamaluddin , Lee, Seung Won , Lee, Wei‐Chen , Leonardi, Matilde, Liu, Xuefeng , Lohner, Valerie , Lorenzovici, László , Lotufo, Paulo A. , Lucchetti, Giancarlo , Lusk, Jay B. , Amin, Hawraz Ibrahim M. , Malhotra, Armaan Kush , Malhotra, Kashish , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Mantovani, LG , Manu, Emmanuel, Marino, Mirko , Martínez, Ramón , Martini, Santi , Martorell, Miquel , Marzo, Roy Rillera , Mathangasinghe, Yasith , Mathews, Elezebeth , Mehmood, Asim , Mehrabani-Zeinabad, Kamran , Menezes, Ritesh G. , Meo, Sultan A , Meretoja, Atte , Meštrović, Tomislav , Sá, Ana Carolina Micheletti Gomide Nogueira de , Minh, Le Huu Nhat , Mirică, Andreea , Мirrakhimov, Erkin М , Mirza‐Aghazadeh‐Attari, Mohammad , Mishra, Ajay Kumar , Mohamed, Ahmed Ismail , Mohammadi, Soheil , Mohammadian-Hafshejani, Abdollah , Mokdad, Ali H. , Molinaro, Sabrina , Momani, Shaher , Ghalibaf, AmirAli Moodi , Moradi, Maryam , Msherghi, Ahmed A.A. , Ansari, Noureddin Nakhostin , Nargus, Shumaila , Natto, Zuhair S. , Nauman, Javaid , DELETE-ME, Nawsherwan, Nayak, Vinod C , Newton, Charles R. , Nigatu, Yeshambel T. , Noubiap, Jean Jacques , Nugen, Fred , Oduro, Michael Safo , Okati‐Aliabad, Hassan , Okeke, Sylvester Reuben , Okekunle, Akinkunmi Paul , Olagunju, Andrew T , Olaiya, Muideen Tunbosun , Olufadewa, Isaac Iyinoluwa , Ornello, Raffaele , Ortiz‐Prado, Esteban , Ouyahia, Amel , Owolabi, Mayowa , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Leonidas D , Pantazopoulos, Ioannis N. , Parikh, Romil R., Patel, Jay , Patel, Urvish , Patoulias, Dimitrios , Pereira, Gavin F , Perianayagam, Arokiasamy , Perna, Simone , Petermann‐Rocha, Fanny , Philip, Anil K. , Пирадов, М. А. , Pradhan, Jalandhar , Puvvula, Jagadeesh , Qasim, Nameer Hashim , Raggi, Alberto , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rahmani, Amir Masoud , Sanati, Ali Rajabpour , Ramasamy, Shakthi Kumaran , Ramazanu, Sheena , Rathish, Devarajan , Rawaf, Salman , Redwan, Elrashdy M , Remuzzi, Giuseppe , Romoli, Michele, Romozzi, Marina , Ross, Allen Guy , Rout, Himanshu Sekhar , Roy, Priyanka , Saad, Aly M A , Saadatian, Zahra , Sabour, Siamak , Sacco, Simona , Sadeghi, Erfan , Saeed, Usman, Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajib, Md Refat Uz Zaman , Saleh, Mohamed A. , Samodra, Yoseph Leonardo , MİLİCEVİC, Milena Santric, Saravanan, Aswini , Sarkar, Tanmay, Sarode, Sachin Chakradhar , Sartorius, Benn , Satpathy, Maheswar , Schneider, Ione Jayce Ceola , Schuermans, Art , Selvaraj, Siddharthan , Senthilkumaran, Subramanian , Sepanlou, Sadaf Ghajarieh , Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shannawaz, Mohammed , Rad, Javad Sharifi, Sharma, Vishal , Shittu, Aminu , Shiue, Ivy , Shlobin, Nathan A. , Siddig, Emmanuel Edwar , Spartalis, Michael , Stanaway, Jeffrey D , Starodubova, Antonina Vladimirovna , Szarpak, Łukasz , Tabatabaeizadeh, Seyed‐Amir , Tabatabaeizadeh, Seyed-Amir, Talaat, Iman Mamdouh , Temsah, Mohamad‐Hani , Thakur, Ramna , Thirunavukkarasu, Sathish, Tiwari, Krishna, Truyen, Thien Tan Tri Tai , Tsai, Daniel Hsiang‐Te , Ullah, Atta , Unnikrishnan, Bhaskaran , Unsworth, Carolyn Anne, Usman, Jibrin Sammani , Valizadeh, Rohollah , Varghese, Joe , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vervoort, Dominique , Villafañe, Jorge Hugo , Vinayak, Manish , Wafa, Hatem A , Walde, Mandaras Tariku, Willeit, Peter , Wolfe, Charles D.A. , Wolfe, Charles D. A., Yamagishi, Kazumasa , Yaribeygi, Habib , Yaya, Sanni , Ye, Pengpeng, Yonemoto, Naohiro , Yu, Chuanhua , Zastrozhin, Michael, Zhang, Chen , Zhang, Zhiqiang, Zielińska, Magdalena , Zyoud, Samer H. , Roth, Gregory A. , Feigin, Valery L. , Kulimbet, Mukhtar , Rahim, Fakher

Mayo Clinic

JAMA Neurology | May 23, 2025 | Volume: 82 | Issue: 8 | Pages: 765

10.1001/jamaneurol.2025.1522 | PMID 40406922 Get It

Importance Nontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure. Objective To estimate the worldwide burden of SAH. Design, Setting, and Participants Based on the repeated cross-sectional Global Burden of Disease (GBD) 2021 study, the global burden of SAH in 1990 to 2021 was estimated. Moreover, the SAH burden was compared with other diseases, and its associations with 14 individual risk factors were investigated with available data in the GBD 2021 study. The GBD study included the burden estimates of nontraumatic SAH among all ages in 204 countries and territories between 1990 and 2021. Exposures SAH and 14 modifiable risk factors. Main Outcomes and Measures Absolute numbers and age-standardized rates with 95% uncertainty intervals (UIs) of SAH incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) as well as risk factor–specific population attributable fractions (PAFs). Results In 2021, the global age-standardized SAH incidence was 8.3 (95% UI, 7.3-9.5), prevalence was 92.2 (95% UI, 84.1-100.6), mortality was 4.2 (95% UI, 3.7-4.8), and DALY rate was 125.2 (95% UI, 110.5-142.6) per 100 000 people. The highest burden estimates were found in Latin America, the Caribbean, Oceania, and high-income Asia Pacific. Although the absolute number of SAH cases increased, especially in regions with a low sociodemographic index, all age-standardized burden rates decreased between 1990 and 2021: the incidence by 28.8% (95% UI, 25.7%-31.6%), prevalence by 16.1% (95% UI, 14.8%-17.7%), mortality by 56.1% (95% UI, 40.7%-64.3%), and DALY rate by 54.6% (95% UI, 42.8%-61.9%). Of 300 diseases, SAH ranked as the 36th most common cause of death and 59th most common cause of DALY in the world. Of all worldwide SAH-related DALYs, 71.6% (95% UI, 63.8%-78.6%) were associated with the 14 modeled risk factors of which high systolic blood pressure (population attributable fraction [PAF] = 51.6%; 95% UI, 38.0%-62.6%) and smoking (PAF = 14.4%; 95% UI, 12.4%-16.5%) had the highest attribution. Conclusions and Relevance Although the global age-standardized burden rates of SAH more than halved over the last 3 decades, SAH remained one of the most common cardiovascular and neurological causes of death and disabilities in the world, with increasing absolute case numbers. These findings suggest evidence for the potential health benefits of proactive public health planning and resource allocation toward the prevention of SAH.
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
Michieli, Laura De , Guida, Gianluigi , Saturi, Giulia , Sena, Guido De , Capovilla, Teresa Maria , Cantone, Anna , Cianca, Alessandro , Lupi, Alessandro , Porcari, Aldostefano , Vergaro, Giuseppe , Albertini, Riccardo, Serenelli, Matteo , Merlo, Marco , Longhi, Simone , Marra, Martina Perazzolo , Iliceto, Sabino , Jaffe, Allan S. , Milani, Paolo , De Michieli, Laura , Guida, Gianluigi , Saturi, Giulia , Sena, Giuseppe , Capovilla, Teresa Maria , Cantone, Anna , Porcari, Aldostefano , Tini, Giacomo , Vergaro, Giuseppe , Cappelli, Francesco , Bianco, Matteo , Mussinelli, Roberta , Musumeci, Beatrice , Perlini, Stefano , Merlo, Marco , Longhi, Simone , Sinagra, Gianfranco , Perazzolo Marra, Martina , Iliceto, Sabino , Jaffe, Allan S. , Palladini, Giovanni , Cipriani, Alberto , Milani, Paolo , Sinigiani, Giulio , Bianco, Matteo , Mussinelli, Roberta , Perlini, Stefano , Palladini, Giovanni

Mayo Clinic

Circulation: Heart Failure | May 15, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circheartfailure.125.012816 | PMID 40371473 Get It

BACKGROUND: Thresholds to define prognosis with hs-cTnI (high-sensitivity cardiac troponin I) have not been systematically addressed in wild-type transthyretin amyloid cardiomyopathy, in part because of the multiplicity of hs-cTnI assays. The aims of this study were: first, to assess the prognostic performance of hs-cTnI measured with different assays in patients with wild-type transthyretin amyloid cardiomyopathy and, second, to identify assay-specific hs-cTnI thresholds for prognosis that could be integrated into staging systems for risk stratification. METHODS: Observational multicenter study of stable wild-type transthyretin amyloid cardiomyopathy patients from different cohorts using the Abbott Architect Stat hs-cTnI assay and the Beckman Coulter Access hs-cTnI assay (testing cohorts) and the Siemens Centaur XPT hs-cTnI assay (validation cohort). Outcome was all-cause mortality. RESULTS: In the Abbott cohort (n=136; median follow-up 22 [13–41] months; 31 [23%] deaths) and Beckman cohort (n=98; median follow-up 19 [12–28] months; 16 [16%] deaths), natural log-transformed hs-cTnI was an independent predictor of mortality (age- and sex-adjusted hazard ratio, 1.62 [95% CI, 1.11–2.35]; P =0.012 and 2.47 [95% CI, 1.48–4.14]; P <0.001, respectively). The best hs-cTnI threshold for 18-month mortality of the combined Abbott/Beckman cohorts (n=234) was 81 ng/L, rounded to 80 ng/L for simplicity of clinical use. A 2-variable staging system (based on the Mayo Clinic system) using hs-cTnI (>80 ng/L) and NPs (natriuretic peptides; NT-proBNP [N-terminal pro-B-type natriuretic peptide] >3000 ng/L or BNP [B-type natriuretic peptide] >250 ng/L) identified 3 groups with progressively worse prognosis. The staging system (using hs-cTnI >80 ng/L and NT-proBNP>3000 ng/L) was then applied to an independent cohort evaluated with the hs-cTnI Siemens assay (n=345, median follow-up 32 [24-42] months, 119 [34%] deaths). The significant differences between the groups were maintained. CONCLUSIONS: In patients with wild-type transthyretin amyloid cardiomyopathy, hs-cTnI is a strong and independent predictor of mortality. A threshold of hs-cTnI of 80 ng/L for these 3 assays provides effective risk stratification alone and in a staging system with NP.
The formal EU-US Meniscus Rehabilitation 2024 Consensus. An ESSKA-AOSSM-AASPT Initiative. Part I –Rehabilitation Management After Meniscus Surgery (Meniscectomy, Repair, Reconstruction)
Pujol, Nicolas , Giordano, Airelle O., Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J., Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Piontek, Tomasz , Schmitt, Laura C. , Benjamin, C., Irrgang, James J. , Rambaud, Alexandre , Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Pujol, Nicolas , Giordano, Airelle O., Wong, Stephanie E. , Becker, Roland, Villa, Francesco Della, Klugarová, Jitka , Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Rambaud, Alexandre, Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Prill, Robert

Mayo Clinic

International Journal of Sports Physical Therapy | May 12, 2025 | Volume: 20 | Issue: 6 | Pages: No page available

10.26603/001c.137095 Get It

Purpose The aim of part-one of this EU-US consensus was to combine literature research and expertise to provide recommendations for the usage of rehabilitation (including physical therapy) of patients undergoing surgical treatment for degenerative meniscus lesions or acute meniscus tears (including meniscectomy, repair, or reconstruction). Prevention programs, non-operative treatment of acute tears and degenerative lesions, return to sports and patient-reported outcome measures (PROMS) will be presented in a part-II article. Methods This consensus followed ESSKA “formal consensus” methodology. For this combined ESSKA (European Society for Sports Traumatology and Arthroscopy), AOSSM (American Orthopedic Society for Sports Medicine), ASSPT (American Academy of Sports Physical Therapy) initiative, 67 experts (26 in the steering group and 41 in the rating group) from 14 countries (USA and 13 European countries) including orthopedic surgeons, sports medicine doctors and physiotherapists were involved. Steering group members established guiding questions, searched the literature, proposed statements. Rating group members assessed the statements according to a Likert scale and provided grades of recommendations reaching final agreement about rehabilitation of the knee after meniscus surgery. Final documents were then assessed by a peer review group to adress the geographical adaptability. Results The overall level of evidence of the literature was low. Of the 19 questions (leading to 29 statements), one received a grade A of recommendation, two a grade B, nine a grade C and 17 a Grade D. Nevertheless, the mean median rating of all questions was 8.2/9 (9 being the highest rating on a scale of 1-9) and the global mean rating was 8.4+/-0.2, indicating a high agreement. Rehabilitation depends on the type of lesion, the treatment performed and is the same after medial or lateral meniscus surgery. Rehabilitation after meniscectomy should follow a criterion-based rehabilitation protocol, based on milestones rather than a time-based protocol. After meniscus repair and reconstruction, rehabilitation should be progressed according to both time and criterion-based milestones. Conclusion Rehabilitation after meniscus surgery is a debated topic that may influence surgical outcomes if not optimally performed. This international formal consensus established clear, updated, and structured recommendations for both surgeons and physiotherapists treating patients after meniscus surgery. Level of Evidence I, Consensus.
The formal EU‐US Meniscus Rehabilitation 2024 Consensus: An ESSKA‐AOSSM‐AASPT initiative. Part I—Rehabilitation management after meniscus surgery (meniscectomy, repair and reconstruction)
Pujol, Nicolas , Giordano, Airelle O., Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J., Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Piontek, Tomasz , Rambaud, Alexandre , Schmitt, Laura C. , Benjamin, C. , Irrgang, James J. , Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Pujol, Nicolas , Wong, Stephanie E. , Becker, Roland, Villa, Francesco Della, Klugarová, Jitka , Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Benjamin, C. , Prill, Robert

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | May 12, 2025 | Volume: 33 | Issue: 8 | Pages: 3002-3013

10.1002/ksa.12674 | PMID 40353298 Get It

Abstract Purpose The aim of part one of this EU‐US consensus was to combine literature research and expertise to provide recommendations for the usage of rehabilitation (including physical therapy) of patients undergoing surgical treatment for degenerative meniscus lesions or acute meniscus tears (including meniscectomy, repair, or reconstruction). Prevention programmes, non‐operative treatment of acute tears and degenerative lesions, return to sports and patient‐reported outcome measures will be presented in a part II article. Methods This consensus followed the European Society for Sports Traumatology and Arthroscopy (ESSKA)'s ‘formal consensus’ methodology. For this combined ESSKA, American Orthopedic Society for Sports Medicine and American Academy of Sports Physical Therapy initiative, 67 experts (26 in the steering group and 41 in the rating group) from 14 countries (US and 13 European countries), including orthopaedic surgeons, sports medicine doctors and physiotherapists were involved. Steering group members established guiding questions, searched the literature and proposed statements. Rating group members assessed the statements according to a Likert scale and provided grades of recommendations, reaching a final agreement about rehabilitation of the knee after meniscus surgery. Final documents were then assessed by a peer review group to address the geographical adaptability. Results The overall level of evidence in the literature was low. Of the 19 questions (leading to 29 statements), 1 received a Grade A of recommendation, 2 a Grade B, 9 a Grade C and 17 a Grade D. Nevertheless, the mean median rating of all questions was 8.2/9 (9 being the highest rating on a scale of 1–9). The global mean rating was 8.4 ± 0.2, indicating a high agreement. Rehabilitation depends on the type of lesion, the treatment performed and is the same after medial or lateral meniscus surgery. Rehabilitation after meniscectomy should follow a criterion‐based rehabilitation protocol, based on milestones rather than a time‐based protocol. After meniscus repair and reconstruction, rehabilitation should be progressed according to both time and criterion‐based milestones. Conclusion Rehabilitation after meniscus surgery is a debated topic that may influence surgical outcomes if not optimally performed. This international formal consensus established clear, updated and structured recommendations for both surgeons and physiotherapists treating patients after meniscus surgery. Level of Evidence Level I, consensus.
EULAR /American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis
Zhao, Yongdong , Oliver, Melissa , Schnabel, Anja , Wang, Zhaoyi , Marino, Achille , Aguiar, Cassyanne L. , Akikusa, Jonathan , Akça, Ümmüşen Kaya , Almeida, Beverley, Appenzeller, Simone , Balay‐Dustrude, Erin , Bilginer, Yelda , Cabral, David A. , Capponi, Martina , Donaldson, Nathan , Egeli, Buğra Han , Iyer, Ramesh S. , Jansson, Annette, Kostik, Inna , Kostik, Mikhail M. , Kovalick, Leonard K., Kozu, Kátia Tomie , Lee, Tzielan , Mahmood, Kamran , Muse, Ian, Mushkin, Alexander, Nowicki, Katherine D. , Nuruzzaman, Farzana , Pham, Trang Sophia, Potts, Lauren, Ramanan, Athimalaipet V., Rogers, Nathan D. , Grim, Andrew W. , Romano, Micol , Rosenwasser, Natalie , Sato, T. Shawn , Soep, Jennifer B. , Stern, Sara , Strauß, Timmy , Taneja, A. , Theos, Alexander C. , Tucker, Lori B. , Vogel, Lisa, Yasin, Shima , Wong, Stephen C. , Bouchalová, Kateřina , Hendry, Alison M., Cain, Kevin C. , Girschick, Hermann , Hedrich, Christian M. , Laxer, Ronald M. , Ferguson, Polly J. , Naden, Raymond P., Özen, Seza , Oliver, Melissa S , Akca, Ummusen Kaya , Appenzeller, Simone , Balay-Dustrude, Erin , Basiaga, Matthew L. , Kostik, Mikhail , Lapidus, Sivia K , Marrani, Edoardo , Mosa, Doaa Mosad , Nowicki, Katherine D , Pardeo, Manuela , Potts, Lauren , Ravelli, Angelo , Tucker, Lori B , Dedeoglu, Fatma , Hedrich, Christian M , Ozen, Seza , Wu, Eveline Y. , Başaran, Özge , Fox, Emily J., Insalaco, Antonella , Lapidus, Sivia , Lenert, Aleksander , Mahmood, Kamran, Mushkin, Alexander, Onel, Karen , Pham, Trang Sophia, Ramanan, Athimalaipet Vaidyanathan , Simonini, Gabriele , Dedeoğlu, Fatma

Mayo Clinic

Arthritis & Rheumatology | May 8, 2025 | Volume: 78 | Issue: 3 | Pages: 537-547

10.1002/art.43137 | PMID 40342207 Get It

Objective To develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR). Methods This international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3) criteria weighting using multicriteria decision analysis, and (4) refinement of weights and threshold score in a development cohort of 441 patients and validation in another cohort of 514 patients. Results The new EULAR/ACR classification criteria for CNO require typical radiographic or magnetic resonance imaging findings and bone pain as an obligatory entry criterion and exclusion criteria of malignancy, infection, vitamin C deficiency, and hypophosphatasia, followed by additive weighted criteria in 5 clinical (site of bone lesions, pattern of bone lesions, age at onset, coexisting conditions, fever) and 4 pathology/laboratory domains (bone biopsy findings if done, anemia, C‐reactive protein level, and erythrocyte sedimentation rate). A total score ≥55 is required for classification as CNO. The new criteria had a sensitivity of 82% and specificity of 98% in the validation cohort. Conclusion These new classification criteria for pediatric CNO developed with international input reflect current views about CNO, have high specificity and good sensitivity, and provide a key foundation for future CNO research.
Abstract 4935: Disentangling the association between age and overall survival in an international cohort of patients with advanced prostate cancer
Sodipo, Michelle O. , Siefkas, Anna , Sauer, Christopher M. , Dogo, Hassan, Waihenya, Charles, Hotte, Sebastién J. , Cathomas, Richard , Enting, Deborah , Khoo, Vincent , Ogo, Chidiebere, McKay, Rana R. , Fischer, Stefanie , Chatwal, Monica , McDermott, Raymond, Davis, Ian D. , Ragin, Camille , Anderson, Simon , Cannon, Laurel, Chan-Cuzydlo, Alyssa, Grant, Marie, Gerke, Travis , George, Daniel J. , Mucci, Lorelei A. , Anderson, Simon G , Hotte, Sebastien J , Guard, Hannah E. , McGrath, Colleen B. , Howard, Lauren E. , Stopsack, Konrad H. , Dreicer, Robert , Esteban, Emilio , Popoola, Ademola , Bjartell, Anders , N., Kim , Tagawa, Scott T. , Ong, Michael M. , Kolinsky, Michael Paul , Mateo, Joaquı́n , Cheng, Heather H. , Szmulewitz, Russell Z , Whang, Young E. , Sharma, Anand , Pouliot, Frédéric , Crabb, Simon J. , Climent, Miguel A., McDermott, Raymond, Badal, Simone , GREAVES, NATALIE S. , Autio, Karen A. , Cannon, Laurel, McManus, Hannah D. , Kantoff, Philip W.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 4935-4935

10.1158/1538-7445.am2025-4935 Get It

Abstract Introduction: Most people who die from prostate cancer are older than 75 years. However, prostate cancer diagnosed at younger ages is often more aggressive. While epidemiologic studies have examined the association between age and survival in patients with prostate cancer overall, the clinical drivers of this relationship in patients with advanced disease remain unclear. We leveraged the International Registry of Men with Advanced Prostate Cancer (IRONMAN, NCT03151629) to (1) quantify the association between age and overall survival and (2) explore whether this association is explained by treatments. Methods: We included 3, 734 patients enrolled from 15 countries with new diagnoses of metastatic hormone sensitive (mHSPC, N=2, 642) or castration resistant prostate cancer (CRPC, N=1, 092). Age at enrollment was categorized as &lt;55, 55-59, 60-64 (reference), 65-69, 70-74, 75-79, 80-84, 85+ years. We computed age-specific death rates (95% confidence intervals [CIs]) by disease state (mHSPC, CRPC) at enrollment. To explore whether this relationship was explained by treatment, we fitted disease state-stratified Cox models and sequentially adjusted for (1) de novo metastatic status and country, and (2) baseline treatment (androgen deprivation therapy [ADT] alone, ADT + androgen receptor pathway inhibitors [ARPI], ADT + chemotherapy, ADT + ARPI + chemotherapy, other). Results: Over 5.5 years of follow-up (median: 3.2 years, IQR: 1.7, 4.8), 995 patients died from any cause. Younger patients were more likely to have de novo metastatic disease. Among those with mHSPC at enrollment, the age-specific death rates per 1, 000 person-years followed a J-shaped pattern: 80 (95% CI: 54, 117) in patients under 55 years, 58 (46, 74) in patients aged 60-64, 102 (78, 133) in patients aged 80-84, and 172 (125, 236) in patients aged 85 and older. The death rates among those with CRPC followed a similar pattern, albeit rates were higher in magnitude: 212 (95% CI: 140, 323) in patients under 55 years, 153 (115, 202) in patients aged 60-64, 200 (155, 258) in patients aged 80-84, and 204 (142, 291) in patients aged 85 and older. After adjusting for disease state, country, and the timing of diagnosis of metastases, death rates were substantially higher for ages 75-79 (HR 1.4; 95% CI 1.1, 1.7), 80-84 years (HR 1.6; 95% CI 1.2, 2.1), and 85 years and older (HR 2.0; 95% CI: 1.5, 2.7) compared to ages 60-64 years. Patients aged under 55 years had 1.4-fold higher death rates (95% CI: 1.0, 1.9) compared to those 60-64 years. After additionally adjusting for baseline treatment, overall survival remained worse for the older patients and the youngest age group with hazard ratios remaining meaningfully unchanged. Conclusion: Age at enrollment is associated with overall survival in people with advanced prostate cancer enrolled in IRONMAN in a J-shaped pattern. This relationship is not explained by differences in baseline treatment. Citation Format: Hannah E. Guard, Michelle O. Sodipo, Colleen B. McGrath, Anna Siefkas, Lauren E. Howard, Konrad H. Stopsack, Christopher M. Sauer, Robert Dreicer, Emilio Esteban, Hassan M. Dogo, Ademola Popoola, Charles Waihenya, Anders Bjartell, Kim N. Chi, Sebastien Hotte, Richard Cathomas, Deborah Enting, Scott Tagawa, Michael Ong, Michael Kolinsky, Vincent Khoo, Joaquin Mateo, Chidiebere N. Ogo, Rana R. McKay, Stefanie Fischer, Heather H. Cheng, Russell Szmulewitz, Young E. Whang, Anand Sharma, Frédéric Pouliot, Simon Crabb, Monica S. Chatwal, Miguel A. Climent, Raymond McDermott, Ian D. Davis, Camille Ragin, Folakemi T. Odedina, Simon Anderson, Simone Badal, Natalie Greaves, Karen A. Autio, Laurel Cannon, Alyssa Chan-Cuzydlo, Marie Grant, Travis Gerke, Hannah D. McManus, Philip W. Kantoff, Daniel J. George, Lorelei A. Mucci, IRONMAN investigator team. Disentangling the association between age and overall survival in an international cohort of patients with advanced prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4935.
Abstract 3630: First-line therapies and subjective cognitive function trajectories among international metastatic hormone-sensitive prostate cancer survivors
Sodipo, Michelle O. , Siefkas, Anna , Drecier, Robert, Dogo, Hassan, Waihenya, Charles, Hotte, Sebastién J. , Cathomas, Richard , Enting, Deborah , Heath, Elisabeth I. , McKay, Rana R. , Fischer, Stefanie, Chatwal, Monica , McDermott, Raymond, Davis, Ian D. , Ragin, Camille, Anderson, Simon , Harrison, Sharon , Cannon, Laurel, Grant, Marie, Chan-Cuzydlo, Alyssa, Gerke, Travis , George, Daniel, Haneuse, Sebastien , Mucci, Lorelei A. , Registry, on behalf of the IRONMAN, Anderson, Simon G , Hotte, Sebastien J , Morgans, Alicia K. , Warner, Erica T. , Rencsok, Emily M. , Howard, Lauren E. , McGrath, Colleen B. , Stopsack, Konrad H. , Sauer, Christopher Martin , Esteban, Emilio , Popoola, Ademola , Bjartell, Anders , N., Kim , Tagawa, Scott T. , Ong, Michael M. , Lorente, David , Cheng, Heather H. , Whang, Young E. , Pouliot, Frédéric , Crabb, Simon J. , Climent, Miguel A., McDermott, Raymond, Ragin, Camille , GREAVES, NATALIE S. , Badal, Simone , Autio, Karen A. , McManus, Hannah D. , Kantoff, Philip W. , Registry, on behalf of the IRONMAN

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3630-3630

10.1158/1538-7445.am2025-3630 Get It

Abstract Introduction: The standard of care for metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with the expanded approval of androgen receptor pathway inhibitors (ARPIs) alongside androgen deprivation therapy (ADT). ADT alone has been shown to affect cognitive function. However, the cognitive impact of distinct treatment combinations remains unclear. We investigated the association between first-line systemic treatments and the trajectory of subjective cognitive function among mHSPC survivors in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). Methods: This analysis included 2435 newly diagnosed mHSPC patients enrolled across 15 countries between July 2017 and August 2024. Treatments were reported by site personnel and physicians. For this analysis, we focused on first-line systemic treatment and classified treatment groups at enrollment as ADT monotherapy (referent), ADT + ARPIs, or ADT + chemotherapy. Subjective cognitive function was assessed via the EORTC QLQ-C30 Cognitive Function subscale, with patient-reported scores (range 0-100) collected at enrollment and every 3 months for up to 5 years; higher scores reflect better cognitive function. Associations were estimated using linear mixed effects models with clustering by study site and country to examine differences at enrollment and across trajectories of subjective cognitive function by first-line treatment, adjusting for demographic and clinical factors. Results: Median age at enrollment was 70 years, with a median follow-up of 1.7 years. 724 (30%) participants were treated with ADT monotherapy, 1317 (54%) with ADT + ARPIs, and 394 (16%) with ADT + chemotherapy. Mean cognitive function scores at enrollment were 85.4 (Standard Deviation [SD] 19.5) for participants treated with ADT monotherapy, 86.7 (SD 17.3) for ADT + ARPIs, and 86.7 (SD 18.0) for ADT + chemotherapy. Cognitive function scores decreased by -0.60 points (95% Confidence Interval [CI] -0.72, -0.48) per year among those treated with ADT monotherapy, with similar rates observed for those treated with ADT + chemotherapy. Participants treated with ADT + ARPIs had a slower decline in cognitive function, with scores decreasing by -0.36 points (95% CI -0.60, -0.08) per year. Conclusion: In this international cohort of mHSPC survivors, subjective cognitive function scores were generally high at enrollment but declined over time. There was no evidence of worse cognitive function in those treated with ADT + ARPIs nor ADT + chemotherapy over time compared to ADT monotherapy. Cognitive functioning is a key component of survivorship, and defining cognitive trajectories associated with first-line treatment can inform supportive interventions, patient treatment decision-making, and clinical guidelines. Citation Format: Michelle O. Sodipo, Alicia K. Morgans, Erica T. Warner, Emily M. Rencsok, Lauren E. Howard, Colleen B. McGrath, Anna Siefkas, Konrad H. Stopsack, Christopher Sauer, Robert Drecier, Emilio Esteban, Hassan M. Dogo, Ademola Popoola, Charles Waihenya, Anders Bjartell, Kim Chi, Sebastien Hotte, Richard Cathomas, Deborah Enting, Scott Tagawa, Michael Ong, David Lorente, Elisabeth Heath, Rana McKay, Stefanie Fischer, Heather H. Cheng, Young E. Whang, Frederic Pouliot, Simon Crabb, Monica Chatwal, Miguel A. Climent, Raymond McDermott, Ian D. Davis, Camille Ragin, Folakemi Odedina, Natalie Greaves, Simone Badal, Simon Anderson, Sharon Harrison, Karen Autio, Laurel Cannon, Marie Grant, Alyssa Chan-Cuzydlo, Travis Gerke, Hannah D. McManus, Philip W. Kantoff, Daniel George, Sebastien Haneuse, Lorelei A. Mucci, on behalf of the IRONMAN Registry. First-line therapies and subjective cognitive function trajectories among international metastatic hormone-sensitive prostate cancer survivors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3630.
Immature Ovarian Teratomas in Anti-NMDA Receptor Encephalitis: A Case Series (P3-8.015)
Nathoo, Nabeela , Simone, Kristen, Buletko, Andrew , Pin, Sophia , Nathoo, Nabeela , Aboseif, Albert , McCombe, Jennifer A.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211091 Get It

Aktualisierung des Modells pathogener CNBP Repeatexpansionen ursächlich für die Myotone Dystrophie Typ 2
Erdmann, H., Wendlandt, Martin , Rost, Simone , Sauer, Mayra , Golibrzuch, M, Timmer, Manuela , Bier, August, Wunderlich, Gilbert , Walter, Maggie C. , Neuhann, Teresa , Holinski‐Feder, Elke , Abicht, Angela, Erdmann, H, Lucas, Morghan C. , Cordts, Isabell , Kleefeld, Felix , Bier, A, Becker, Kerstin , Kleinle, Stephanie , Wenninger, Stephan , Schoser, Benedikt

Mayo Clinic

Nervenheilkunde | March 11, 2025 | Volume: 44 | Issue: No issue available | Pages: No page available

10.1055/s-0044-1801526 Get It

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Zarif, Talal El , Denu, Ryan , Abdel‐Wahab, Noha , Freeman, Dory , Hayeck, Salim, Anderson, Élizabeth , Goodman, Rachel , Johnson, Douglas B. , Grynberg, Shirly , Shapira, Ronnie, Kwan, Jennifer M. , Long, Georgina V. , Haykal, Tarek , Kojima, Yuki , Yonemor, Kan, Trevino, Alexandra , Hui, Gavin , Drakaki, Alexandra, El‐Am, Edward , Al‐Hader, Ahmad, Babu, P. Narendra , Li, Mingjia , Jones, N. , Herrera, M., Foderaro, Simone , Kim, Chul , Sackstein, Paul , Desai, Aakash , Smith, Caleb J. , Korolewicz, James , Lopetegui‐Lia, Nerea , Funchain, Pauline , Choudhary, Arrush, Asnani, Aarti , Stukalin, Igor , Gallegos, Jesús Antonio Ocejo , Nusrat, Sanober , Malvar, Carmel, McKay, Rana R. , Neilan, Tomas G. , Naqash, Abdul Rafeh , Baena, Javier , El Zarif, Talal , Goodman, Rachel S , Kim, Chul , Desai, Aakash P , Cortellini, Alessio , Pinato, David J , Navani, Vishal , Ocejo Gallegos, Jesus Antonio , Funchain, Pauline , Long, Georgina V , Naqash, Abdul Rafeh , Grynberg, Shirly , Espinar, Javier Baena , Alaiwi, Sarah Abou , Macaron, Walid , Vasbinder, Alexi L. , Woodford, Rachel , Dent, Susan , Kojima, Yuki, Tandon, Ankita, Akhter, Nausheen , Yang, Eric H. , Kozaily, Elie , Farhat, Elias Bou , Mittra, Arjun , Jones, Nicholas, Baena, Javier, Nana, Frank Aboubakar , Parikh, Kaushal , Cortellini, Alessio , Pinato, David J. , Meyers, Daniel E. , Trent, Jonathan C. , Choueiri, Toni K. , Korolewicz, James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 3, 2025 | Volume: 13 | Issue: 3 | Pages: e009364

10.1136/jitc-2024-009364 | PMID 40032601 Get It

Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included. Treatment-related adverse events (trAEs) were graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) were evaluated by Response Evaluation Criteria in Solid Tumors V.1.1 when available. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Results Among 110 pts, median age at ICI initiation was 65 (IQR: 59–75). Median follow-up time since ICI initiation was 36 (95% CI: 26 to 51) months. Melanoma (38%, n=42) and non-small cell lung cancer (24%, n=26) were the most common. 68 (62%) patients received ICIs as first-line, and 29 (26%) patients were treated with combination anti-programmed death-1 and anti-cytotoxic T-lymphocyte antigen 4. The most common location of cardiac metastasis was in the atria (37%, n=41) and ventricles (35%, n=39). 15 patients (13.6%) had bilateral cardiac/pericardial metastasis, 44 (40%) had left-sided, and 43 (39.8%) had right-sided. At ICI initiation, 21% (n=23) had a cardiac thrombus. Cardiology referrals and cardiac MRIs at the time of cancer diagnosis were completed on 58 (53%) and 52 (47%) patients, respectively. Cardiac events occurred in 40 (36%) patients, including arrhythmias (n=14, 13%), arterial/venous emboli (n=4, 3.6%), and cardiac tamponade (n=3, 2.7%). 53 (47%) patients developed trAEs; most common were colitis/diarrhea (n=16, 15%), dermatitis (n=13, 12%), and hepatitis (n=9, 8.2%). ICI-related major cardiac trAEs occurred in 2 (1.8%) patients. 22 patients (20%) developed grade ≥3 trAE. Patients with multiple cardiac metastases had significantly lower responses to ICI-based regimens compared with patients with single cardiac metastasis (11% vs 63%, p=0.02). For melanoma, ORR, median PFS, and median OS were 38%, 9.0 months, and 28.9 months, respectively. 83% of patients with melanoma had concordant responses in overall disease burden and cardiac disease. 91 patients discontinued ICIs, and the main reason was progression or death in 55 (49%) patients. Conclusions Among patients with pre-existing cardiac metastasis, ICIs demonstrated meaningful clinical efficacy with no increase in safety signals. Most patients had concordant responses in the overall disease burden and cardiac mass. Multidisciplinary teams are crucial for the appropriate management of patients with cardiac metastasis.